Amsterdam, the Netherlands – As part of the company’s focus on the development of advanced monitoring solutions, Royal Philips (NYSE: PHG; AEX: PHIA) today announced the launch of its IntelliVue patient monitoring platform with Masimo rainbow® SET technology. Philips also offers its customers the option to add rainbow® SET to existing IntelliVue monitors, and the company is working to integrate the technology into its Philips SureSigns and Philips Efficia patient monitoring platforms.
In conjunction with the appropriate Philips patient monitoring platform, Masimo rainbow® SET technology analyzes multiple wavelengths of light to accurately measure total hemoglobin (SpHb™), oxygen content (SpOC®), carboxyhemoglobin (SpCO™), methemoglobin (SpMet®) and Pleth Variability Index (PVI®) noninvasively and continuously. Continuous monitoring of rainbow SpHb™ on a Philips monitor at the point-of-care provides clinicians with real-time visibility to changes in hemoglobin in between invasive blood sampling.
To ensure that customers have choice of SpO2 pulse oximetry measurement technology, Philips continues to offer Philips FAST SpO2 pulse oximetry and Covidien’s OxiMax SpO2 pulse oximetry, depending on the patient monitoring platform.
Philips offers a comprehensive portfolio of patient monitoring solutions ranging from bedside monitors to wearable patient monitors, combined with clinical decision support tools and mobile applications to provide immediate access to centrally held patient data. More than 275 million patients were monitored with Philips’ patient monitors in 2014.